Turning a corner: Private market posts best month in yearsCore private market metrics suggest positive momentum is brewing and investor sentiment is improving
Turning a corner: Private market posts best month in years
Trading
Data
Solutions
Insights
About
CG Oncology, based in Irvine, Calif., was founded in 2010 by CEO Arthur Kuan. The company, which was last valued at $405 million in September 2022, is a developer of genetically engineered oncolytic immunotherapy treatments for individuals with advanced cancer.
Last September, the company announced an oversubscribed $120 million Series E funding round led by ORI Capital, Longitude Capital and Decheng Capital. The company said it will use the new capital to advance its lead programs toward FDA review and broaden its drug pipeline to address other unmet needs in urologic cancer. Its lead drug candidate, CG0070, has reached Phase 3 testing as a monotherapy for non-muscle invasive bladder cancer.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 8/2/2023 | Series F | $105.02MM raised | $XXX.XX | $XXX.XX |
| 9/30/2022 | Series E | $120MM raised | $XXX.XX | $XXX.XX |
| 12/10/2020 | Series D | $47.3MM raised | $XXX.XX | $XXX.XX |
| 3/18/2019 | Series C | $22MM raised | $XXX.XX | $XXX.XX |
| 8/5/2015 | Series B | $10MM raised | $XXX.XX | $XXX.XX |
| 7/28/2014 | Series A-1 | $3.57MM raised | $XXX.XX | $XXX.XX |
